Drug Trial Radar · NCT05686759
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Apr 13, 2023
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients
Conditions
- Hepatitis B
Interventions
Undiluted I.V.-Hepabig inj(GC5103)Biological
undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
Diluted I.V.-Hepabig inj(GC5103)Biological
Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events occurred during clinical trialsTime frame: during 20 weeks post first Investigational product administration
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Inje University Haeundae Paik Hospital
Busan, South Korea · Recruiting
Chungnam National University Hospital
Daejeon, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea · Recruiting
Ajou University Medical Center
Suwon, Gyeonggi-do, South Korea · Recruiting
Asan Medical Center
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.